A phase III, randomized study of the investigational agent TAK-700 plus prednisone for patients with chemotherapy-naïve metastatic castration-resistant prostate cancer (mCRPC).
F. Saad
Consultant or Advisory Role - Millennium
Research Funding - Millennium
H. Akaza
Consultant or Advisory Role - Millennium
Honoraria - Takeda
M. A. Eisenberger
Honoraria - Millennium
J. Nelson
Consultant or Advisory Role - Millennium
H. I. Scher
Consultant or Advisory Role - Aragon Pharmaceuticals (U); Bristol-Myers Squibb (U); Centocor Ortho Biotech (U); Enzon; Medivation (U); Millennium; Veridex (U)
Stock Ownership - Johnson & Johnson
K. Suzuki
Consultant or Advisory Role - Millennium
Honoraria - Takeda
Research Funding - Takeda
M. Wirth
Consultant or Advisory Role - Takeda
I. J. Webb
Employment or Leadership Position - Millennium
J. Wang
Employment or Leadership Position - Millennium
D. MacLean
Employment or Leadership Position - Millennium
R. De Wit
Consultant or Advisory Role - Millennium
Honoraria - Millennium